|Brief Description||Principal Investigator|
To evaluate the safety and tolerability of AMG 232.
To determine the maximum-tolerated dose (MTD) of AMG 232.
To define the pharmacokinetics (PK) of AMG 232 in subjects with relapsed/refractory acute myelois leukemias (AMLs).
|Grunwald, Michael Richard|
I. To maintain a Childhood Cancer Registry for infants, children, adolescents, and young adults with cancer.
II. To utilize clinical and biological data to help determine eligibility or stratification, based on childhood cancer disease classification schemas, for potential enrollment of research subjects onto Children's Oncology Group (COG) therapeutic clinical trials.
III. To develop a well annotated childhood cancer biobank for current and future research through the collection of biospe
|Kaplan, Joel Adam|
|To determine the maximum tolerated dose (MTD), the dose limiting toxicities(DLT) and the dose of FT-1101 recommended for future phase 2 studies (RP2D) for patients with relapsed refractory acute leukemia or high-risk MDS.||Grunwald, Michael Richard|
|Primary: Evaluate spleen response rate and symptom response rate of 2 dose regimens of imetelstat in subjects with intermediate-2 or high-risk MF who are relapsed after or refractory to JAK inhibitor treatment.||Grunwald, Michael Richard|
To determine the ability of CD34+ cell selection using the CliniMACS® device as the sole
GVHD prophylaxis to prevent severe (grade III-IV) acute GVHD in recipients of
alternative donor (mismatched related donor and unrelated donor) hematopoietic stem
|Gilman, Andrew Lee|
|The primary objective of this study is to examine the incidence of neutrophil recovery of > or = to 500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licensed.||Gilman, Andrew Lee|
|To determine the maximal tolerated dose (MTD) and/or tolerable dose of escalating doses of clofarabine starting from 20mg/m2/day to 40mg/m2/day from Day 1 to Day 5 in combination with mitoxantrone 12mg/m2/day on Day 3-6 as reinduction therapy for children, adolescents and young adults with poor risk refractory/relapsed acute leukemia or high grade NHL.||Oesterheld, Javier E|
|To report the incidence of chronic kidney disease (CKD), metabolic syndrome, and osteopenia at one and two-years following allogeneic HCT for hematologic malignancy.||Gilman, Andrew Lee|
Primary: Evaluate antitumor activity in patients with previously treated CLL
Secondary: Evaluate addition of ublituximab to ibrutinib on complete response, minimal residual disease negativity (MRD)and effect on safety profile. This study will also evaluate progression free survival.